The Russian Direct Investment Fund (RDIF), which is behind the production and distribution of the Russian-made vaccine Sputnik V, announced that 100 million doses of the medication may be provided for the EU during the next quarter of the year.
Earlier this month, the Russian vaccine was authorised by Hungary, which became the first EU member state to approve Sputnik V.
After completion of the main part of mass vaccination in Russia, RDIF can provide EU with 100 mln doses of #SputnikV vaccine for 50 mln people in Q2 2021 (subject to EMA approval). Sputnik V is registered in 15 countries and documents have been submitted for EMA rolling review. pic.twitter.com/27Ncwns24n— Sputnik V (@sputnikvaccine) January 29, 2021
European countries have recently faced some issues with their mass vaccination plans since the UK-Swedish pharma giant AstraZeneca declared it would cut Q1 2021 deliveries of its vaccine to the bloc by up to 60 percent, while guaranteeing deliveries to the United Kingdom.
In response, European Council President Charles Michel warned that Brussels may take "urgent measures to ensure effective vaccine production and supply", hinting at the possible suspension of Pfizer vaccine exports from the EU.